4.8K(top 0.1%)
papers
110.4K(top 0.1%)
citations
123(top 0.1%)
h-index
240(top 0.1%)
g-index
5.4K
all documents
123.8K
doc citations
7.1K
citing journals

Top Articles

#TitleJournalYearCitations
1Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialLancet, The20183,542
2Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancet, The20173,224
3Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialLancet, The20172,771
4Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialLancet Oncology, The20181,816
5Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet, The20171,749
6Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyLancet Oncology, The20201,363
7Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialJournal of Clinical Oncology20201,255
8Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine20181,253
9Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid CarcinomaJAMA Oncology20161,192
10High performance plasma amyloid-β biomarkers for Alzheimer’s diseaseNature20181,180
11High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast MaterialRadiology20141,112
12The Chemokine Superfamily RevisitedImmunity2012914
13Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialLancet, The2017753
14Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology2020746
15Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung CancerJAMA Oncology2018735
16Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular CarcinomaJournal of Clinical Oncology2020723
17Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 studyLancet Oncology, The2014678
18NASH limits anti-tumour surveillance in immunotherapy-treated HCCNature2021649
19Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaJournal of Hepatology2022568
20CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyLancet Oncology, The2013555
21Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trialLancet, The2022537
22IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerBritish Journal of Cancer2015533
23Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 studyLancet Oncology, The2016533
24Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialLancet Oncology, The2022526
25CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)Annals of Oncology2019512
26A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAXJournal of Bone and Mineral Research2016508
27Guidelines for Management of Idiopathic Normal Pressure Hydrocephalus: Second EditionNeurologia Medico-Chirurgica2012506
28Diagnosis and management of Guillain–Barré syndrome in ten stepsNature Reviews Neurology2019463
29Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung CancerJAMA Oncology2020446
30Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2019418
31Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialGut2020411
32Overlapping demyelinating syndromes and anti–N‐methyl‐D‐aspartate receptor encephalitisAnnals of Neurology2014405
33Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trialLancet Oncology, The2017398
34Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal SocietyEsophagus2015383
35Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resectionJournal of Hepatology2018360
36Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trialJournal of Thoracic and Cardiovascular Surgery2019347
37Japanese guidelines for the management of acute pancreatitis: Japanese Guidelines 2015Journal of Hepato-Biliary-Pancreatic Sciences2015332
38Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)Japanese Journal of Clinical Oncology2019329
39JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary SyndromeCirculation Journal2019324
40CCR4 and its ligands: from bench to bedsideInternational Immunology2015314
41Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinomaJournal of Hepatology2020310
42Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor ImmunityClinical Cancer Research2016309
43Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 UpdateLiver Cancer2021307
44Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyCancer Science2016305
45Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma2022298
46Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summaryArchives of Osteoporosis2012284
47Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancerAnnals of Oncology2013284
48Outcomes for out-of-hospital cardiac arrests across 7 countries in Asia: The Pan Asian Resuscitation Outcomes Study (PAROS)Resuscitation2015279
49Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary SyndromeCirculation Journal2014277
50Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung CancerJournal of Thoracic Oncology2021274